Neoadjuvant and adjuvant therapy (NAT/AT) treatment patterns and clinical characteristics in a real-world cohort of US patients with HR+/HER2-early breast cancer (eBC)

被引：0
|
作者：
Downer, Mary K. [1 ]
Craggs, Christopher [1 ]
Dhillon, Preet [1 ]
Luhn, Patricia [1 ]
Flores-Avile, Carlos [2 ]
Tan, Amie [1 ]
Patre, Monika [3 ]
Schimmoller, Frauke [1 ]
Crnjevic, Tanja Badovinac [3 ]
机构：
[1] Genentech Inc, San Francisco, CA 94080 USA
[2] Genesis Res, Hoboken, NJ USA
[3] F Hoffmann La Roche & Cie AG, Basel, Switzerland
来源：
CANCER RESEARCH | 2021年 / 81卷 / 04期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
PS7-23
引用
收藏
页数：2
相关论文
共 50 条
  • [1] Patient profiles, management and treatment patterns in HR+, HER2-early breast cancer in a real-world setting in Spain
    Martin, Miguel
    Saenz, Jose Angel Garcia
    Blancas, Isabel
    Molero, Alberto
    Atienza, Manuel
    Cervera, Jose Manuel
    Brown, Jacqueline
    Rider, Alex
    Williams, Rhys
    Alba, Emilio
    CANCER RESEARCH, 2022, 82 (04)
  • [2] Real-world treatment of HER2+and HR+/HER2-early breast cancer in county areas of China
    Ji, Y.
    Wang, J.
    Dai, G.
    Zhou, F.
    Meng, Q.
    Wu, Q.
    Qu, H.
    Liu, H.
    Liu, M.
    Tian, Y.
    Tan, X.
    He, W.
    Qin, Z.
    Tang, H.
    Luo, G.
    Liu, Y.
    Ren, Y.
    Luo, J.
    Wang, M.
    Lu, P.
    ANNALS OF ONCOLOGY, 2023, 34 : S1474 - S1474
  • [3] Clinicopathologic features, Adjuvant Treatment Patterns and Clinical Outcomes of HR+/HER2-Early Breast Cancer in China
    Li, Q.
    Jiang, M.
    Liu, J.
    Zhang, M.
    Xu, B.
    BREAST, 2025, 80
  • [4] Real-world risk of recurrence and treatment outcomes with adjuvant endocrine therapy in patients with stage II-III HR+/HER2-early breast cancer
    O'Shaughnessy, Joyce
    Tolaney, Sara M.
    Yardley, Denise A.
    Hart, Lowell
    Razavi, Pedram
    Fasching, Peter A.
    Janni, Wolfgang
    Schwartzberg, Lee
    Kim, Julia
    Akdere, Murat
    McDermott, Courtney
    Khakwani, Aamir
    Pathak, Purnima
    Graff, Stephanie L.
    BREAST, 2025, 81
  • [5] Real-world treatment patterns of adjuvant endocrine therapy and ovarian suppression in premenopausal HR+/HER2+breast cancer
    Sukumar, Jasmine S.
    Sardesai, Sagar
    Ni, Andy
    Williams, Nicole
    Johnson, Kai
    Quiroga, Dionisia
    Ramaswamy, Bhuvana
    Wesolowski, Robert
    Cherian, Mathew
    Stover, Daniel G.
    Gatti-Mays, Margaret
    Pariser, Ashley
    Sudheendra, Preeti
    George, Mridula A.
    Lustberg, Maryam
    CANCER MEDICINE, 2024, 13 (12):
  • [6] Neoadjuvant (neoadj) and adjuvant (adj) treatment patterns in HER2-positive early breast cancer (EBC): Analysis of US real-world oncology data
    Dhillon, Preet K.
    Flores, Carlos
    Sanglier, Thibaut
    Antao, Vincent
    Tesarowski, David
    Fung, Anita
    Incerti, Devin
    Restuccia, Eleonora
    Luhn, Patricia
    CANCER RESEARCH, 2021, 81 (04)
  • [7] A real-world retrospective study of the use of Ki-67 testing and treatment patterns in patients with HR+, HER2-early breast cancer in the United States
    Brown, Jacqueline
    Scardo, Savannah
    Method, Michael
    Schlauch, Dan
    Misch, Amanda
    Picard, Shaita
    Hamilton, Erika
    Jones, Suzanne
    Burris, Howard
    Spigel, David
    BMC CANCER, 2022, 22 (01)
  • [8] A multinational real-world study on HR+, HER2-early stage breast cancer patients' disease awareness, satisfaction, and involvement in treatment decisions
    Rider, A.
    Method, M.
    Williams, R.
    Piercy, J.
    Clayton, E.
    Brown, J.
    ANNALS OF ONCOLOGY, 2020, 31 : S336 - S336
  • [9] Real-world (RW) risk of recurrence among patients (pts) diagnosed with stage II-III HR+/HER2-early breast cancer (EBC) treated with endocrine therapy (ET) in the US.
    Razavi, Pedram
    Ahmed, Mehnaj
    Roush, Ashley
    Parikh, Rohan
    Hitchens, Abigail
    Shen, Sherry
    Safonov, Anton
    Jhaveri, Komal L.
    Robson, Mark E.
    Peacock, Nancy Walker
    Ma, Yanjun
    Santarsiero, Elizabeth Chertow
    Ganapathy, Vaidyanathan
    Shah, Rohan M.
    Amefule, Adaeze Q.
    Lteif, Agnes
    Blakely, L. Johnetta
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [10] Prosigna (PAM50) to predict response to neoadjuvant chemotherapy (NAC) in HR+/HER2-early breast cancer (EBC) patients.
    Jimenez Rodriguez, Begona
    Lavado Fernandez, Ana Isabel
    Ribelles, Nuria
    Sanchez-Rovira, Pedro
    Vicioso, Luis
    Alvarez, Martina
    de Luque, Vanessa
    Ramirez Tortosa, Cesar
    Buckingham, Wesley
    Schaper, Carl
    Jeiranian, Arthur
    Dowidar, Naeem
    Ferree, Sean
    Villar, Ester
    Zarcos, Irene
    Sanchez-Munoz, Alfonso
    Gonzalez-Hermoso, Carlos
    Llacer Perez, Casilda
    Prat, Aleix
    Alba, Emilio
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
12345